180 Life Sciences Provides Follow-Up Information on Oxford University and the Company’s Successful Dupuytren’s Phase 2b Clinical Trial Results
Yahoo! Finance
PALO ALTO, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today provided follow-up information on the top line results of Oxford University and the Company’s Phase 2b clinical trial for Dupuytren’s disease announced on December 1, 2021. Dr. James Woody, 180 Life Sciences Chi
Continue Reading